Ista Gains North American Rights To Bepotastine For Nasal Allergies From Tanabe Seiyaku
This article was originally published in The Pink Sheet Daily
Executive Summary
H1 receptor antagonist will enter clinic for nasal indication in late 2008/early 2009, firm tells “The Pink Sheet” DAILY.
You may also be interested in...
Ista CEO Vince Anido: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Exec discusses mid-stage pipeline, recent deal with Tanabe Seiyaku for bepotastine and the market for nasal allergy products - and Ista as a possible acquisition target.
Ista CEO Vince Anido: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Exec discusses mid-stage pipeline, recent deal with Tanabe Seiyaku for bepotastine and the market for nasal allergy products - and Ista as a possible acquisition target.
Ista CEO Eyes Bepreve Launch In 2009
CEO Vince Anido tells “The Pink Sheet” DAILY that the firm plans to file an NDA for the allergic conjunctivitis treatment in the second half of 2008.